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Summary
Activation via the T lymphocyte cell surface molecule CD28 provides a potent amplification
signal for interleukin 2 (IL2) production in several in vitro systems. TheB lymphocyte activation
antigen, B7/BB1, is a natural ligand for CD28 . Herewe investigate the role ofCD28 and B7/BB1
in primary activation of CD4+ T lymphocytes stimulated with allogeneic B lymphoblastoid
cell lines. A subset of peripheral CD4+ T cells that is unresponsive to crosslinking of CD3/T
cell receptor (TCR) withCD3 monoclonal antibody (mAb) does proliferate in response to allogeneic
B lymphoblasts . TCR binding to allogeneic major histocompatibility complex antigens was an
absolute requirement for activation of these cells because mAbs to either CD3 or human
histocompatibility leukocyte antigen (HLA) class II completely inhibited activation . CD28 and
B7/BB1 antibodies inhibited T cell proliferation 90% and84%, respectively . Similar results were
obtained with the total CD4+ T lymphocyte population . Crosslinking ofHLADR antigens
on small, resting B cells induced rapid expression of 117/11111, which peaked at 6 h and returned
to baseline levels within 18 h. These data demonstrate that CD28-B7/BB1 binding provides
an important early second signal for alloactivation of CD4+ T lymphocyte by B lymphoblasts.
The results also suggest that T cells interacting with allogeneic restingB cellsmay induce B7/BB1
expression in the alloantigen-presenting cell as a consequence of interaction between the TCR
and class II molecules .
Primary antigen-specific immune responses require TCR-
Ag/MHC occupancy (first signal) and additional stimuli
from theAPC (second signal) (reviewed in reference 1) . Simi-
larly, alloantigen activation ofT cells also requires costimula-
tory signals in addition to TCR occupancy by the allogeneic
MHC antigen . Peripheral blood dendritic cells and anti-Ig-
activated B lymphoblasts are potent stimulators, in contrast
to monocytes and small resting B cells (2) . Several cell sur-
face molecules onT lymphocytes are potential candidates for
providing the "second signal" necessary for alloactivation as
a result ofbinding to their natural ligand : CD2/LFA3, LFA
1/ICAM-1 and -2, CD4/HLA class II, CD8/HLA class I
(reviewed in reference 3), and CD28/117-BB1(4, 5) . We have
recently described a subset of peripheral CD4+, CD45RA+
T cells that is unresponsive to CD3/TCR crosslinking with
anti-CD3 in presence of autologous APC (6) . We report here
that this CD4+ T cell subset proliferates in response to al-
logeneicB lymphoblastoid cell lines (B-LCL) . The responses
are potently inhibited by mAbs to two sets of cell surface-
expressed receptor ligands: TCRCD3/HLA class II and
CD28/117-11111. Similar results were obtained with the total
CD4+ T cell population. Crosslinking ofHLADR mole-
cules on resting B lymphocytes induces B7/BB1 expression
which peaks within 6 h, suggesting that binding ofB7/BB1
to CD28 provides an important second signal for primary
alloactivation of CD4+ T cells by B lymphoblasts.
Materials and Methods
mAbs Used.
￿
Anti-HLA class I (HLAA,B,C) : W6/32 (IgG2a)
and 4E (HLA-B,C and Aw19) (IgG2a) ; anti-HLA-DR : L243
(IgG2a) and HB10a (IgG2b) ; anti-HLA-DQ : TU 22 ; anti-CD2:
9.6 (IgG2a) and 9-1 (IgG3); anti-CD3 : OKT3 (IgG2a) and SP34
(IgG2a) ; anti-CD28 : 9.3 (IgG2a) ; anti-CD8: OKT8 (IgG2a) and
SA-19-11 (IgGi); anti-CD25 : 6G (IgG2a) ; anti-CD5 : H65 (IgGi)
and 6-2 (IgG2a); anti-CD37 : G28-1 (IgGl) ; anti-CD22 : G28-7
(IgGi) ; anti-B7/BBI : BBl (IgM) ; anti-CD54 (ICAM-1) : LB-2
(IgG2b) ; anti-CD45 : 9.4 (IgG2a), reactive with all chains ofCD45;
and anti-CDlc : M241 (IgGi) .
Isolation ofCD4+ T Lymphocyte Populations.
￿
Peripheral blood
CD4' T cells were isolated as previously described (6) . Anti-
CD3-unresponsive CD4+ cells were isolated from CD4* T lym-
phocytes that had been cultured for 40 h at 37°C with the CD3
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(Amgen 'Biol ., Thousand Oaks, CA) . The cells were negatively
selected with mAbs L243 and 6G (6) .
B Lymphocyte Preparations .
￿
Tonsillar B cells were isolated as pre-
viously reported (7) on discontinuous Percoll gradients (Pharmacia
Fine Chemicals, Piscataway, NJ) of 55%, 45%, and 35% . Cells
that pelleted below 55% Percoll were used .
Primary Mixed Lymphocyte Culture.
￿
T cells from different prepa-
rations were incubated at 5 x 1IN cells/well in 96-well plates in
RPMI 1640 supplemented with 15% human serum (Gibco Labora-
tories, Grand Island, NY) with equal number ofirradiated (9,000
rad) EBVtransformedB lymphocytes (B-LCL) as stimulators. The
proliferation was measured by the ['H]TdR uptake (6) . Inhibition
ofMLR with mAbs was performed by preincubating T cells for
30 min at 4°C with anti-CD3 (OKT3) and anti-CD28 (9.3). Stimu-
lator B-LCL were preincubated in the same manner with HLA
class II mAbs (anti-DR, L243, and anti-DO, Tu22), and anti-
B7/BB1 (BBI) . Anti-HLA class I (W6/32 and 4E) were added to
both responding and stimulator cells . The percentage ofinhibition
was calculated relative to the maximum proliferative response in
unblocked control cultures.
Induction ofBB1 .
￿
Small, dense, tonsillar B cells were treated
with 5 jug/ml or either biotinylated HB10a, 9.4, or G28-1 for 30
min on ice, washed, and then incubated at 37°C with 20 Pg/ml
avidin (Sigma Chemical Co., St . Louis, MO) in biotin-free RPMI
1640 with 10% dialyzed FCS for the indicated times . In some ex-
periments B cells were treated with 10 ng/ml of12-0-tetradecanoyl-
phorbol 13-acetate (PMA) (Sigma Chemical Co.) . After incuba-
tion, cells were stained with either BB1-FITC or LB-2-FITCmAb.
Results
Anti-CD3-unresponsive CD4+ T cells proliferated to
anti-CD3 and anti-CD2 stimulation only when exogenous
rIIr2 was supplied, indicating that anti-CD3 or anti-CD2
mAbs did not provide sufficient activation signals for endog-
enous IIr2 production . The addition ofanti-CD28 (mAb 9.3)
to the anti-CD2 combination resulted in a strong mitogenic
response (6) . Thus, crosslinking of CD3/TCR with anti-
CD3 in the presence of APC was not sufficient to induce
proliferation of the anti-CD3-unresponsive CD4+ T cell
subset . Allogeneic B-LCL provided, however, all the signals
necessary to induce proliferation in the anti-CD3-unresponsive
subset of CD4+ cells (Fig . 1 and Table 1) .
The effects of mAbs on the allogeneic response by the
anti-CD3-unresponsive CD4+ T cells are shown in Fig. 1 .
Cell proliferation was completely abrogated by CD3 mAb
and by HLA class II mAbs. CD28 mAb 9.3 and mAb BB1
inhibited cell proliferation by 87% and 93%, respectively .
This inhibition of MLR by CD28 mAb was similar to that
previously obtained with total peripheral T cells (8) . Anti-
HLA class I mAbs W6/32 plus 4E also inhibited the MLR
by 76% . In contrast, mAbs binding either CD1c, CD5, or
CD22 did not inhibit MLR (data not shown) .
A summary of the proliferative in vitro responses of total
CD4+ and anti-CD3-unresponsive CD4+ T lymphocytes is
presented in Table 1 . The results indicate that the anti-CD3-
unresponsive CD4+ subset proliferated less in response to al-
loantigens compared with total CD4+ cells . In spite of this
difference, the pattern as well as the degree of blocking of
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￿
Inhibition of Allogeneic Responses by Peripheral CD4*
T Lymphocytes and Anti-CD3-unresponsive CD4* T lymphocytes
CD28 Ligand Provides Costimulatory Signal for Alloactivation of T Cells
Anti-CD3-
unresponsive
PeripheralCD4T lymphocytes and anti-CD3-unresponsive CD4 T cells
were isolated as described in Materials and Methods . Allogeneic B-LCL
(irradiated 9,000 rad) were used as stimulator cells . mAbs were used in
dilutions ranging from 6.25 to 300 hg/ml, as described in Materials and
Methods . Maximum percent inhibition is shown . The allogeneic responses
ofCD4* T cells differed significantly from the response by anti-CD3-
unresponsive CD4* cells (p = 0.0025, Wilcoxon Rank Test) .
primaryMLR caused by the mAbs were similar for both T
cell preparations . This would imply that the activation pro-
cess is initiated in the same manner in both total CD4+ T
cells and anti-CD3-unresponsive T cells and is further de-
pendent on the same costimulatory secondary signals . Anti-
CD28 inhibitedMLR when added during the first 24 h of
culture, while this antibody had no significant inhibitory effect
when added at 72 h (data not shown) .
Efficient crosslinking ofHLA class II antigens on B cells
transmits an activation signal(s) to humanB cells (9) . As shown
in Fig . 2 A, crosslinking ofHLADR antigens on B cells
stimulated an increased expression ofB7/BB1 . The effect was
specific since (a) PMA did not induce increases in B7/BB1
although it did increase CD54 in some cells, and (b) cross-
linking CD37, which like class II is expressed at high levels
on B cells, did not induce significant increases in B7/BB1 .
Crosslinking CD45 on B cells also increasedB7/BB1 levels,
but unlike stimulation via HLA class II, signaling via CD45
also rendered a dramatic increase in CD54 in some cells . The
Responder cells
Mean (cpm)
Range (cpm)
CD4* T cells
82,036
17,717-187,555
CD4+ T Cells
45,200
10,415-74,640
No . of experiments 13 12
Anti-CD3
Mean (percent inhibition) 99 99
Range (percent inhibition) 99-100 98-99
No . of experiments 3 2
Anti-HLA class II
Mean (percent inhibition) 86 97
Range (percent inhibition) 66-96 96-97
No . of experiments 5 2
Anti-CD28
Mean (percent inhibition) 82 90
Range (percent inhibition) 62-96 87-91
No . of experiments 4 4
Anti-B7/BB1
Mean (percent inhibition) 75 84
Range (percent inhibition) 62-89 75-93
No . of experiments 3 2ANTI-CD3-UNRESPONSIVE, CD4+ T LYMPHOCYTES
STIMULATOR : B-LCL allo x
Figure 1 .
￿
Inhibition of the allogeneic proliferation of anti-CD3-unresponsive CD4+ T cells by mAbs . Freshly isolated anti-CD3-unresponsive CD4'
lymphocytes (see Materials and Methods) were cultured with irradiated EBVtransformed B cells (BLCL.) for 6 d . At the onset of the cultures the
following mAbs were added : anti-CD3 (OKT3), anti-HLA class II (L243 and Tu22), anti-HLA class I (W6/32 and 4E), anti-CD28 (9.3), and anti-
B7/BBI (BBI), in concentrations as indicated. The maximum proliferative response in the absence ofantibodies was determined in the control unblocked
cultures (T+BLCL,) . The purity of the responder population was assessed by the lack of proliferation when stimulated with anti-CD3 in the presence
of 20% APC (T + anti-CD3 + APC) .
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Figure2 .
￿
Effect ofHLA class 11 (HLA-DR) crosslinking on expression
of B7/BB1 and CD54/ICAM-1 by B lymphocytes. (A) Dense tonsillar
B cells were treated withPMA or mAb as indicated for 6 h at 37°C and
then were stained with fluorescein-conjugated mAb to B7/BBI (left) or
CD54/ICAM-1 (right). Control unstained cellsare shown in the top panel.
Data represent one of four experiments. (B and C) Kinetics ofthe induc-
tion of B7/BBl expression by crosslinkingMHC class II molecules . Dense
tonsillar B cells were treated for times indicated with either medium only
(O), avidin only ("), biotinylated G28-1 anti-CD37 mAb with (N) or
without (0) crosslinking avidin, or biotinylated HB10a anti-DR mAb
with (" ) or without (A) crosslinking avidin. Stimulated cells were then
stained with fluorescein-conjugatedmAb to detect either B7/BB1 expres-
sion (B) or CD54/ICAM-1 expression (C) .
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0kinetics of class II induction ofB7/BB1 was relatively rapid
peaking about 6-8 h after stimulation and then waning (Fig.
2 B), while ICAM-1 was not upregulated (Fig. 2 C) .
Discussion
Recent data suggest that only activated APC are able to
mediate antigen presentation to T cells and that a key second
signal provided by APC is not a cytokine but a cell surface
molecule (reference 10 and reviewed in reference 1) . Cross-
linking ofMHC class II antigens on B cells by mAb leads
to an increase in the second messengers such as intracellular
free Cat' andcAMP, and activation of phospholipase C and
new protein tyrosine phosphorylation (9) . The importance
of the signals delivered to the APC through MHC class II
molecules is indicated by the observation that B lymphoma
cells expressing truncated class II antigens display profound
defects in antigen presentation (11) . We here demonstrate that
crosslinking ofHLADR antigens on resting B lymphocytes
induces maximal expression ofB7/BBl antigen after only
6 h . Taken together these data indicate that presentation of
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